Furthermore, ZNF217, an m6A methyl-transferase inhibitor, inhibits the m6A modification of several pluripotency factor mRNAs, including NANOG, KLF4 and SOX2 in breast cancer to promote the CSC-like phenotype and breast cancer metastasis under hypoxic conditions [73]. Here, NANOG is linked to breast cancer.